MAPT and tauopathy: Although zebrafish tauopathy models are limited, several new findings on pathological features and signaling factors for tauopathy have been discovered, and novel GSK3β inhibitors and Tau assembly modulators were validated as potential therapeutic targets for tauopathy using these zebrafish Tau models.